Oncogenic kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia

Cancer Cell

Volumn 25, Issue 5, 2014, Pages 621-637

  McAllister, Florencia ^a,b   Bailey, Jennifer M ^b   Alsina, Janivette ^b   Nirschl, Christopher ^a   Sharma, Rajni ^b   Fan, Hongni ^a   Rattigan, Yanique ^b   Roeser, Jeffrey C ^b   Lankapalli, Rachana H ^a   Zhang, Hao ^d   Jaffee, Elizabeth M ^a   Drake, Charles G ^a   Housseau, Franck ^a   Maitra, Anirban ^a,b   Kolls, Jay K ^c   Sears, Cynthia L ^a   Pardoll, Drew M ^a   Leach, Steven D ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 22; INTERLEUKIN 4; INTERLEUKIN 6; MUCIN 5AC; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UVOMORULIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER GROWTH; CANCER INFILTRATION; CHRONIC PANCREATITIS; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; HELPER CELL; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MICROENVIRONMENT; MOUSE; NONHUMAN; ONCOGENE K RAS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; CARCINOMA IN SITU; CELL TRANSFORMATION, NEOPLASTIC; CHEMOPREVENTION; EPITHELIAL CELLS; HEMATOPOIETIC SYSTEM; HUMANS; INFLAMMATION; INTERLEUKIN-17; MICE; MICE, TRANSGENIC; PANCREAS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; RECEPTORS, INTERLEUKIN-17; SIGNAL TRANSDUCTION; TH17 CELLS;

EID: 84900315697     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.03.014     Document Type: Article

References (61)

1. Bailey J.M., Leach S.D. Signaling pathways mediating epithelial- mesenchymal crosstalk in pancreatic cancer: Hedgehog, Notch and TGFbeta. Pancreatic Cancer and Tumor Microenvironment 2012, Trivandrum, India. P.J. Grippo, H.G. Munshi (Eds.).
2. Bailey J.M., Alsina J., Rasheed Z.A., McAllister F.M., Fu Y.Y., Plentz R., Zhang H., Pasricha P.J., Bardeesy N., Matsui W., et al. DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in pre-invasive pancreatic cancer. Gastroenterology 2013, 146:245-256.
3. Bayne L.J., Beatty G.L., Jhala N., Clark C.E., Rhim A.D., Stanger B.Z., Vonderheide R.H. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and Tcell immunity in pancreatic cancer. Cancer Cell 2012, 21:822-835.
4. Braun R.K., Ferrick C., Neubauer P., Sjoding M., Sterner-Kock A., Kock M., Putney L., Ferrick D.A., Hyde D.M., Love R.B. IL-17 producing gammadelta Tcells are required for a controlled inflammatory response after bleomycin-induced lung injury. Inflammation 2008, 31:167-179.
5. Chaturvedi P., Singh A.P., Moniaux N., Senapati S., Chakraborty S., Meza J.L., Batra S.K. MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Mol. Cancer Res. 2007, 5:309-320.
6. Chu G.C., Kimmelman A.C., Hezel A.F., DePinho R.A. Stromal biology of pancreatic cancer. J.Cell. Biochem. 2007, 101:887-907.
7. Chung A.S., Wu X., Zhuang G., Ngu H., Kasman I., Zhang J., Vernes J.M., Jiang Z., Meng Y.G., Peale F.V., et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat. Med. 2013, 19:1114-1123.
8. Clark C.E., Hingorani S.R., Mick R., Combs C., Tuveson D.A., Vonderheide R.H. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007, 67:9518-9527.
9. Corcoran R.B., Contino G., Deshpande V., Tzatsos A., Conrad C., Benes C.H., Levy D.E., Settleman J., Engelman J.A., Bardeesy N. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res. 2011, 71:5020-5029.
10. Cruz-Monserrate Z., Abd-Elgaliel W.R., Grote T., Deng D., Ji B., Arumugam T., Wang H., Tung C.H., Logsdon C.D. Detection of pancreatic cancer tumours and precursor lesions by cathepsin E activity in mouse models. Gut 2012, 61:1315-1322.
11. Fujisawa T., Velichko S., Thai P., Hung L.Y., Huang F., Wu R. Regulation of airway MUC5AC expression by IL-1beta and IL-17A; the NF-kappaB paradigm. J.Immunol. 2009, 183:6236-6243.
12. Fukuda A., Wang S.C., Morris J.P., Folias A.E., Liou A., Kim G.E., Akira S., Boucher K.M., Firpo M.A., Mulvihill S.J., Hebrok M. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 2011, 19:441-455.
13. Garcia-Hernandez Mde.L., Hamada H., Reome J.B., Misra S.K., Tighe M.P., Dutton R.W. Adoptive transfer of tumor-specific Tc17 effector Tcells controls the growth of B16 melanoma in mice. J.Immunol. 2010, 184:4215-4227.
14. Genovese M.C., Van den Bosch F., Roberson S.A., Bojin S., Biagini I.M., Ryan P., Sloan-Lancaster J. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 2010, 62:929-939.
15. Gnerlich J.L., Mitchem J.B., Weir J.S., Sankpal N.V., Kashiwagi H., Belt B.A., Porembka M.R., Herndon J.M., Eberlein T.J., Goedegebuure P., Linehan D.C. Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer. J.Immunol. 2010, 185:4063-4071.
16. Greer J.B., Whitcomb D.C. Inflammation and pancreatic cancer: an evidence-based review. Curr. Opin. Pharmacol. 2009, 9:411-418.
17. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
18. Guerra C., Schuhmacher A.J., Cañamero M., Grippo P.J., Verdaguer L., Pérez-Gallego L., Dubus P., Sandgren E.P., Barbacid M. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 2007, 11:291-302.
19. Habbe N., Shi G., Meguid R.A., Fendrich V., Esni F., Chen H., Feldmann G., Stoffers D.A., Konieczny S.F., Leach S.D., Maitra A. Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc. Natl. Acad. Sci. USA 2008, 105:18913-18918.
20. Hassan M.M., Bondy M.L., Wolff R.A., Abbruzzese J.L., Vauthey J.N., Pisters P.W., Evans D.B., Khan R., Chou T.H., Lenzi R., et al. Risk factors for pancreatic cancer: case-control study. Am. J. Gastroenterol. 2007, 102:2696-2707.
21. He D., Li H., Yusuf N., Elmets C.A., Li J., Mountz J.D., Xu H. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J.Immunol. 2010, 184:2281-2288.
22. He S., Fei M., Wu Y., Zheng D., Wan D., Wang L., Li D. Distribution and clinical significance of th17 cells in the tumor microenvironment and peripheral blood of pancreatic cancer patients. Int. J. Mol. Sci. 2011, 12:7424-7437.
23. Hoshi H., Sawada T., Uchida M., Saito H., Iijima H., Toda-Agetsuma M., Wada T., Yamazoe S., Tanaka H., Kimura K., et al. Tumor-associated MUC5AC stimulates invivo tumorigenicity of human pancreatic cancer. Int. J. Oncol. 2011, 38:619-627.
24. Ito Y., Usui T., Kobayashi S., Iguchi-Hashimoto M., Ito H., Yoshitomi H., Nakamura T., Shimizu M., Kawabata D., Yukawa N., et al. Gamma/delta Tcells are the predominant source of interleukin-17 in affected joints in collagen-induced arthritis, but not in rheumatoid arthritis. Arthritis Rheum. 2009, 60:2294-2303.
25. Ivanov I.I., McKenzie B.S., Zhou L., Tadokoro C.E., Lepelley A., Lafaille J.J., Cua D.J., Littman D.R. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006, 126:1121-1133.
26. Jacobetz M.A., Chan D.S., Neesse A., Bapiro T.E., Cook N., Frese K.K., Feig C., Nakagawa T., Caldwell M.E., Zecchini H.I., et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2013, 62:112-120.
27. Kimura A., Naka T., Kishimoto T. IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. Proc. Natl. Acad. Sci. USA 2007, 104:12099-12104.
28. Kopp J.L., von Figura G., Mayes E., Liu F.F., Dubois C.L., Morris J.P., Pan F.C., Akiyama H., Wright C.V., Jensen K., et al. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 22:737-750.
29. Leonardi C., Matheson R., Zachariae C., Cameron G., Li L., Edson-Heredia E., Braun D., Banerjee S. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N.Engl. J. Med. 2012, 366:1190-1199.
30. Lesina M., Kurkowski M.U., Ludes K., Rose-John S., Treiber M., Klöppel G., Yoshimura A., Reindl W., Sipos B., Akira S., et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011, 19:456-469.
31. Liu Y., Mei J., Gonzales L., Yang G., Dai N., Wang P., Zhang P., Favara M., Malcolm K.C., Guttentag S., Worthen G.S. IL-17A and TNF-α exert synergistic effects on expression of CXCL5 by alveolar type II cells invivo and invitro. J.Immunol. 2011, 186:3197-3205.
32. Löhr M., Schmidt C., Ringel J., Kluth M., Müller P., Nizze H., Jesnowski R. Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res. 2001, 61:550-555.
33. Maisonneuve P., Marshall B.C., Lowenfels A.B. Risk of pancreatic cancer in patients with cystic fibrosis. Gut 2007, 56:1327-1328.
34. Muzumdar M.D., Tasic B., Miyamichi K., Li L., Luo L. A global double-fluorescent Cre reporter mouse. Genesis 2007, 45:593-605.
35. Numasaki M., Lotze M.T., Sasaki H. Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts. Immunol. Lett. 2004, 93:39-43.
36. Ogura H., Murakami M., Okuyama Y., Tsuruoka M., Kitabayashi C., Kanamoto M., Nishihara M., Iwakura Y., Hirano T. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 2008, 29:628-636.
37. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., Madhu B., Goldgraben M.A., Caldwell M.E., Allard D., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
38. Papp K.A., Leonardi C., Menter A., Ortonne J.P., Krueger J.G., Kricorian G., Aras G., Li J., Russell C.B., Thompson E.H., Baumgartner S. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N.Engl. J. Med. 2012, 366:1181-1189.
39. Prasad N.B., Biankin A.V., Fukushima N., Maitra A., Dhara S., Elkahloun A.G., Hruban R.H., Goggins M., Leach S.D. Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res. 2005, 65:1619-1626.
40. Prévot P.P., Simion A., Grimont A., Colletti M., Khalaileh A., Van den Steen G., Sempoux C., Xu X., Roelants V., Hald J., et al. Role of the ductal transcription factors HNF6 and Sox9 in pancreatic acinar-to-ductal metaplasia. Gut 2012, 61:1723-1732.
41. Provenzano P.P., Cuevas C., Chang A.E., Goel V.K., Von Hoff D.D., Hingorani S.R. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 21:418-429.
42. Pylayeva-Gupta Y., Lee K.E., Hajdu C.H., Miller G., Bar-Sagi D. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 2012, 21:836-847.
43. Rhim A.D., Mirek E.T., Aiello N.M., Maitra A., Bailey J.M., McAllister F., Reichert M., Beatty G.L., Rustgi A.K., Vonderheide R.H., et al. EMT and dissemination precede pancreatic tumor formation. Cell 2012, 148:349-361.
44. Sarkar S., Cooney L.A., White P., Dunlop D.B., Endres J., Jorns J.M., Wasco M.J., Fox D.A. Regulation of pathogenic IL-17 responses in collagen-induced arthritis: roles of endogenous interferon-gamma and IL-4. Arthritis Res. Ther. 2009, 11:R158.
45. Schwarzenberger P., La Russa V., Miller A., Ye P., Huang W., Zieske A., Nelson S., Bagby G.J., Stoltz D., Mynatt R.L., et al. IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for invivo evaluation of cytokines. J.Immunol. 1998, 161:6383-6389.
46. Shen F., Ruddy M.J., Plamondon P., Gaffen S.L. Cytokines link osteoblasts and inflammation: microarray analysis of interleukin-17- and TNF-alpha-induced genes in bone cells. J.Leukoc. Biol. 2005, 77:388-399.
47. Singh A.P., Moniaux N., Chauhan S.C., Meza J.L., Batra S.K. Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res. 2004, 64:622-630.
48. Sparmann A., Bar-Sagi D. Ras-induced interleukin-8 expressionplays a critical role in tumor growth and angiogenesis. Cancer Cell 2004, 6:447-458.
49. Stagg J., Loi S., Divisekera U., Ngiow S.F., Duret H., Yagita H., Teng M.W., Smyth M.J. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc. Natl. Acad. Sci. USA 2011, 108:7142-7147.
50. Strobel O., Dor Y., Alsina J., Stirman A., Lauwers G., Trainor A., Castillo C.F., Warshaw A.L., Thayer S.P. Invivo lineage tracing defines the role of acinar-to-ductal transdifferentiation in inflammatory ductal metaplasia. Gastroenterology 2007, 133:1999-2009.
51. Takahashi H., Numasaki M., Lotze M.T., Sasaki H. Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunol. Lett. 2005, 98:189-193.
52. Teng M.W., Vesely M.D., Duret H., McLaughlin N., Towne J.E., Schreiber R.D., Smyth M.J. Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. Cancer Res. 2012, 72:3987-3996.
53. van den Berg W.B., Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat. Rev. Rheumatol. 2009, 5:549-553.
54. Vizio B., Novarino A., Giacobino A., Cristiano C., Prati A., Ciuffreda L., Montrucchio G., Bellone G. Potential plasticity of T regulatory cells in pancreatic carcinoma in relation to disease progression and outcome. Exp. Ther. Med. 2012, 4:70-78.
55. Wakita D., Sumida K., Iwakura Y., Nishikawa H., Ohkuri T., Chamoto K., Kitamura H., Nishimura T. Tumor-infiltrating IL-17-producing gammadelta Tcells support the progression of tumor by promoting angiogenesis. Eur. J. Immunol. 2010, 40:1927-1937.
56. Wang L., Yi T., Kortylewski M., Pardoll D.M., Zeng D., Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J.Exp. Med. 2009, 206:1457-1464.
57. Wittel U.A., Pandey K.K., Andrianifahanana M., Johansson S.L., Cullen D.M., Akhter M.P., Brand R.E., Prokopczyk B., Batra S.K. Chronic pancreatic inflammation induced by environmental tobacco smoke inhalation in rats. Am. J. Gastroenterol. 2006, 101:148-159.
58. Wu S., Rhee K.J., Albesiano E., Rabizadeh S., Wu X., Yen H.R., Huso D.L., Brancati F.L., Wick E., McAllister F., et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 Tcell responses. Nat. Med. 2009, 15:1016-1022.
59. Xiao M., Wang C., Zhang J., Li Z., Zhao X., Qin Z. IFNgamma promotes papilloma development by up-regulating Th17-associated inflammation. Cancer Res. 2009, 69:2010-2017.
60. Xie S., Li J., Wang J.H., Wu Q., Yang P., Hsu H.C., Smythies L.E., Mountz J.D. IL-17 activates the canonical NF-kappaB signaling pathway in autoimmune B cells of BXD2 mice to upregulate the expression of regulators of G-protein signaling 16. J.Immunol. 2010, 184:2289-2296.
61. Zhang Q., Liu S., Ge D., Zhang Q., Xue Y., Xiong Z., Abdel-Mageed A.B., Myers L., Hill S.M., Rowan B.G., et al. Interleukin-17 promotes formation and growth of prostate adenocarcinoma in mouse models. Cancer Res. 2012, 72:2589-2599.